Nov 2, 2026
Editas Medicine (EDIT) Projected to Announce Earnings on Monday
Editas Medicine (EDIT) is expected to report its Q3 2026 earnings before market open on Monday, November 9th, with analysts forecasting a loss of $0.21 per share and revenue of $4.54 million. The company's earnings call is scheduled for November 10th at 4:00 p.m. ET. Editas Medicine previously surpassed estimates in Q2, reporting a smaller loss and higher revenue than expected, and currently holds a "Moderate Buy" consensus rating from Wall Street analysts.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Neutral
Oct 28, 2026
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
Shares of several gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rallied after the FDA issued draft guidance to accelerate personalized treatments for rare genetic diseases. This new guidance allows companies to file one application for multiple versions of a gene-editing treatment if they make the same kind of genetic correction, enabling faster expansion with lab tests instead of full trials. Prime Medicine saw the largest gains, building on recent company-specific updates, including dosing the first patient in a Phase 1/2 trial for Wilson disease using prime editing therapy.
Company relevance
91.34%
Company sentiment
Bullish
Overall sentiment
Bullish